73 Results for "

RI

" in MedChemExpress (MCE) Product Catalog:
Products (73)

73 Results for "RI" in MCE Product Catalog:

22
22 Publications Verification
Cat. No.: HY-13012
CAS No.: 446859-33-2
Purity:  99.92%
Synonyms: E-616452; SJN 2511
Research Areas:  

Metabolic Disease

RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-14818
CAS No.: 203120-17-6
Purity:  99.27%
Synonyms: R 125489
Target:  

Influenza Virus

Research Areas:  

Infection

Laninamivir (R 125489) is a potent influenza neuraminidase (NA) inhibitor with IC50s of 0.90 nM, 1.83 nM and 3.12 nM for avian H12N5 NA (N5), pH1N1 N1 NA (p09N1) and A/RI/5+/1957 H2N2 N2 (p57N2), respectively .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-15317
CAS No.: 415713-60-9
Purity:  99.83%
Target:  

RAD51

Research Areas:  

Cancer

RI-1 is a RAD51 inhibitor, with IC50s ranging from 5 to 30 μM. RI-1 binds covalently to the surface of RAD51 protein at cysteine 319. RI-1 inactivates RAD51 by directly binding to a protein surface that serves as an interface between protein subunits in RAD51 filaments. RI-1 can disrupt homologous recombination in human cells .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99171
CAS No.: 1129435-60-4

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology Cancer

Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-114322
CAS No.: 2306193-61-1
Purity:  98.00%
Research Areas:  

Cancer

VZ185 is a BRD9 and BRD7 PROTAC degrader, with DC50 values of 1.76 nM and 4.5 nM, respectively, in RI-1 cells; and DC50 values of 4 nM and 34 nM, respectively, in HEK293 cells. VZ185 hijacks the CRL2 VHL E3 ubiquitin ligase complex to induce ubiquitination and subsequent proteasomal degradation of BRD9 and BRD7. VZ185 can be used in research related to acute myeloid eosinophilic leukemia and malignant rhabdoid tumors .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-16904
CAS No.: 1417162-36-7
Target:  

RAD51

Research Areas:  

Cancer

RI-2 is a reversible RAD51 inhibitor, with an IC50 of 44.17 μM, and specifically inhibits homologous recombination repair in human cells.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0620
CAS No.: 102841-43-0
Mulberroside C is one of the main bioactive components in white mulberry (Morus alba L.). Mulberroside C exhibits antiplatelet, antiviral and neutrophil-regulating activities, and binds to EV-A71 VP1 with a Kd value of 1.289 nM. Mulberroside C reduces the phosphorylation level of ERK, promotes the phosphorylation of IP3RI at the Ser 1756 site, and decreases calcium influx and calcium mobilization. Mulberroside C inhibits the expression of P-selectin (P-selectin). Mulberroside C upregulates the cyclic nucleotide signaling pathway in human platelets. Mulberroside C binds to IL-23R, upregulates the expression of G-CSF, GM-CSF and RASGRP1, and activates the RAS/ERK signaling pathway. Mulberroside C promotes neutrophil maturation, accelerates the recovery of leukopenia, and enhances the antibacterial activity of neutrophils. Mulberroside C inhibits the replication of hepatitis C virus in replicon cells. Mulberroside C prevents the uncoating and genome release of EV-A71, and inhibits the synthesis of viral proteins and RNA. Mulberroside C can be used in studies related to thrombosis-mediated cardiovascular diseases, chemotherapy- and radiotherapy-induced leukopenia, hepatitis C virus infection, and hand, foot and mouth disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-126972A
Purity:  98.02%
Target:  

RAD51

Research Areas:  

Cancer

RI(dl)-2 TFA is a potent and selective RAD51-mediated D-loop formation inhibitor with an IC50 of 11.1 μM. RI(dl)-2 TFA does not influence RAD51 binding to ssDNA and inhibits homologous recombination (HR) activity in human cells (IC50 of 3.0 μM) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P78525
Purity:  ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: AAT5; ACVRLK4; ALK-5; LDS1A; LDS2A; SKR4; tbetaR-I; TGFB1R1; TGF-beta RI; TGFbetaRI; TGFBR1; TGF-bRI; TGFR-1; tβR-I; TGF-β RI; TGFβRI
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-13012G
CAS No.: 446859-33-2
Synonyms: E-616452 (GMP); SJN 2511 (GMP)
RepSox (E-616452) (GMP) is a RepSox (HY-13012) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. RepSox is a potent and selective TGF-β-RI/ALK5 inhibitor .
loading...
    loading...
Cat. No.: HY-P3325
CAS No.: 2147724-76-1
Synonyms: D-P8RI
Target:  

VEGFR

Research Areas:  

Inflammation/Immunology

P8RI (D-P8RI) is a biomimetic peptide of CD31 and a CD31 agonist. P8RI binds to the juxtamembrane amino acid sequence of the ectodomain of CD31, shows an immunosuppressive effect through restoration of the CD31 inhibitory pathway .
loading...
    loading...
Cat. No.: HY-P10861A
Target:  

Tau Protein

Research Areas:  

Neurological Disease

RI-AG03 acetate is a proteolytically stable tau aggregation inhibitor that crosses the blood-brain barrier and exhibits oral efficacy. RI-AG03 acetate inhibits tau aggregation and promotes the formation of alternative amorphous aggregates that are non-amyloidogenic. RI-AG03 acetate mediates cellular uptake through direct membrane penetration and macropinocytosis, and its conjugation with cell-penetrating peptide sequences (CPPs) enhances the binding of cells to liposomes. RI-AG03 acetate suppresses aggregation-dependent neurodegenerative and behavioral phenotypes, and extends the lifespan of Drosophila models of tauopathy. RI-AG03 acetate can be used for research on tau-related diseases such as Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-160167
CAS No.: 2662512-15-2
Synonyms: DZD8586
Target:  

Src Btk

Research Areas:  

Inflammation/Immunology Cancer

Birelentinib (DZD8586) is an orally effective, selective, non-covalent inhibitor targeting LYN tyrosine kinase and BTK tyrosine kinase, capable of penetrating the blood-brain barrier. Birelentinib exhibits concentration-dependent antiproliferative effects in RI-1 cells and diffuse large B-cell lymphoma (DLBCL) cell lines carrying BTK resistance mutations (such as C481X, V416L, etc.). Birelentinib blocks both BTK-dependent and independent signaling of the B-cell receptor (BCR), thereby inhibiting tumor cell proliferation and inducing cell death. Birelentinib can be used in research to overcome resistance to existing covalent and non-covalent BTK inhibitors in B-cell non-Hodgkin lymphoma (B-NHL) .
loading...
    loading...
Cat. No.: HY-148382
CAS No.: 2763831-53-2
Purity:  ≥98.0%
RI-962 is a potent and selective receptor-interacting protein kinase 1 (RIPK1) inhibitor. RI-962 inhibits RIPK1 with an IC50 value of 35.0 nM. RI-962 can be used for the research of nervous system diseases and inflammatory diseases .
loading...
    loading...
Cat. No.: HY-P10861
Target:  

Tau Protein

Research Areas:  

Neurological Disease

RI-AG03 is a proteolytically stable tau aggregation inhibitor that crosses the blood-brain barrier and exhibits oral efficacy. RI-AG03 inhibits tau aggregation and promotes the formation of alternative amorphous aggregates that are non-amyloidogenic. RI-AG03 mediates cellular uptake through direct membrane penetration and macropinocytosis, and its conjugation with cell-penetrating peptide sequences (CPPs) enhances the binding of cells to liposomes. RI-AG03 suppresses aggregation-dependent neurodegenerative and behavioral phenotypes, and extends the lifespan of Drosophila models of tauopathy. RI-AG03 can be used for research on tau-related diseases such as Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-138601
CAS No.: 104579-03-5
Purity:  98.72%
5'-O-DMT-N4-Bz-5-Me-dC is a modified nucleoside. 5'-O-DMT-2'-O-TBDMS-rI can be used in the synthesis of deoxyribonucleic acid or nucleic acid.
loading...
    loading...
Cat. No.: HY-120994B
CAS No.: 129693-13-6
Target:  

PKA

Sp-8-CPT-cAMPS, a cAMP analog, is a potent and selective activator of the cAMP-dependent protein kinas A (PKA I and PKA II). Sp-8-CPT-cAMPS selects site A of RI compares to site A of RII by 153-fold and site B of RII compares to site B of RI by 59-fold .
loading...
    loading...
Cat. No.: HY-138608
CAS No.: 119898-59-8
Purity:  99.17%
5'-O-DMT-Ri can be used in the synthesis of oligoribonucleotides .
loading...
    loading...
Cat. No.: HY-P99478
CAS No.: 163796-60-9

Target:  

IFNAR

Research Areas:  

Inflammation/Immunology

Bifarcept is an interferon receptor type I (IFN-RI) fusion protein. Bifarcept can bind interferon receptors and prolong its serum half-life .
loading...
    loading...
Cat. No.: HY-171130
Target:  

MicroRNA

Research Areas:  

Others

Cy3 MicroRNA Antagomir Negative Control is a Cy3-labeled MicroRNA Antagomir Negative Control (HY-RI04602A). The sequence of MicroRNA Antagomir Negative Control is derived from cel-mir-239b. It has minimal sequence identity with miRNAs in human, mouse, and rat .
loading...
    loading...